The weekly litigation news digest is live. Subscribe now
Glp-1 Receptor Agonists In Dementia - EP4054620
The patent EP4054620 was granted to Novo Nordisk on May 29, 2024. The application was originally filed on Nov 5, 2020 under application number EP20803489A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4054620
- Application Number
- EP20803489A
- Filing Date
- Nov 5, 2020
- Status
- Granted And Under Opposition
- Apr 27, 2024
- Publication Date
- May 29, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Semaglutide, a GLP-1 receptor agonist, offers a new therapeutic approach for preventing or slowing dementia progression. Administering semaglutide to individuals with metabolic syndrome or other conditions associated with increased dementia risk, such as diabetes, cardiovascular disease, or obesity, has been shown to reduce the risk of dementia in clinical trials. The treatment's mechanism of action involves modulating metabolic pathways to improve cognitive function and reduce inflammation, with potential benefits extending to other conditions like diabetes and cardiovascular disease.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (17) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents